Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the Patient.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Associations of Alzheimer's disease with inpatient hospital costs and with quality-adjusted life years: evidence from conventional and Mendelian randomization analyses in the UK Biobank.Cost effectiveness and resource allocation : C/E · 2025
   Article
2. Access in all areas? A round up of developments in market access and HTA: part 5.Journal of comparative effectiveness research · 2024
   Article
3. Is the price right? Paying for value today to get more value tomorrow.BMC medicine · 2024
   Article

Corrections and comments

• Comment on
  Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as